An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge

Inclusion Criteria for receipt of Study Drug:

• Male or female.
• 18 to 55 years of age, inclusive, at time of screening.
• Healthy on the basis of physical examination, medical history, and vital signs performed at screening.
• Healthy on the basis of clinical laboratory tests performed at screening.
• Must pass the comprehension assessment indicating that the participant understands the purpose, procedures, and potential risks and benefits of the study, after reading the informed consent and after the investigator or designee has provided detailed information on the study and answered the potential participant's questions.
• Must have a body mass index between 18.0 and 35.0 kg/m2, inclusive.
• Must have a normal electrocardiogram (ECG, test which displays a person's heartbeat) at screening.
• Must have a blood pressure (after lying face up for greater than or equal to 5 minutes) between 90 and 140 mmHg systolic and less than or equal to 90 mmHg diastolic at screening.
• Must complete the informed consent process independently and without assistance and sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.
• All persons of childbearing potential must have a negative pregnancy test at screening.
• A volunteer must be:
• Not of childbearing potential, or
• Of childbearing potential and practicing a highly effective, preferably user independent method of contraception and agrees to remain on a highly effective method while receiving study drug and until 90 days after the last dose of study drug.
• A person of childbearing potential must agree not to donate eggs for the purposes of assisted reproduction during the study and for 90 days after the last dose of study drug.
• During the study and for 90 days after the last dose of study drug, persons who are having sexual relationships in which their partner may become pregnant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person. Persons who are having sexual relationships in which their partner may become pregnant should also be advised of the benefit for their partner to use a highly effective method of contraception as condoms may break or leak.
• A sperm-producing participant must agree not to donate sperm for the purpose of reproduction during the study and for 90 days after the last dose of study drug.
• Must be willing and able to adhere to the study requirements and lifestyle restrictions:
• Do not take any restricted medications/treatments
• Agree to follow all study requirements
• No unusual strenuous exercise
• Must not donate blood or blood products within 6 months after last dose of study drug
• Must not participate in another investigational study during the study or within 90 days after last dose of study drug
• Must not travel to any dengue-endemic region (as defined by the United States Centers for Disease Control and Prevention
• Must limit the use of food or drinks/beverages containing alcohol to the absolute minimum from 48 hours before first dose of study drug until Day 85.
• Must refrain from consumption of grapefruit or grapefruit juice, energy drinks, excessive use of caffeine from 7 days before first dose of study drug until Day 85
• May not use drugs of abuse (including amphetamine, barbiturate, cocaine, methadone, and opiates) until 3 weeks after the last dose of study drug.
• Should not consume any food containing poppy seeds or codeine-containing formulation starting 72 hours before the screening visits and before any visit during the follow-up phase (to avoid a false-positive urine drug test).
• Should follow the instructions for the timing of the standardized meals
• Available for the duration of the study, which is approximately 85 days after injection of the dengue virus.

Exclusion Criteria for receipt of Study Drug:

• History of liver or renal impairme